<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02010905</url>
  </required_header>
  <id_info>
    <org_study_id>NL44943.018.13</org_study_id>
    <nct_id>NCT02010905</nct_id>
  </id_info>
  <brief_title>Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System</brief_title>
  <acronym>Redefine</acronym>
  <official_title>Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Interuniversity Cardiology Institute of the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The prevalence of adult patients with congenital heart disease (CHD) has steadily&#xD;
      increased over the last decades, due to the advances in cardiac surgery. A large number of&#xD;
      these patients cope with right ventricular (RV) volume or pressure overload, largely caused&#xD;
      by residual lesions after cardiac surgery in childhood. Previous RV overload due to pulmonary&#xD;
      regurgitation in Tetralogy of Fallot (TOF) can lead to RV dysfunction. These findings warrant&#xD;
      close surveillance of RV function, and adequate and evidence-based pharmacological therapy to&#xD;
      reduce both morbidity and mortality in this young patient group. The&#xD;
      renin-angiotensin-aldosterone system (RAAS) is activated in patients with ventricular&#xD;
      failure, irrespective of the effected (left or right) ventricle. Angiotensin converting&#xD;
      enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB's) are drugs which act as&#xD;
      inhibitors of RAAS. Previously, large trials have demonstrated the beneficial effect of&#xD;
      angiotensin converting enzyme (ACE) inhibitors on morbidity and mortality in patients with&#xD;
      acquired left ventricular (LV) dysfunction. ARB's have a similar effect as ACE inhibitors in&#xD;
      patients with acquired LV dysfunction but discontinuation because of side effects such as&#xD;
      cough is less frequent. In TOF patients with RV overload due to pulmonary regurgitation,&#xD;
      pulmonary valve replacement leads to a decrease in RV size and pulmonary regurgitation.&#xD;
      Current guidelines advise empiric use of RAAS inhibitors for right ventricular dysfunction in&#xD;
      adult patients with congenital heart disease. However, the actual effect of RAAS inhibition&#xD;
      on right ventricular dysfunction in adult TOF patients without severe valvular lesions has&#xD;
      not been sufficiently investigated. Therefore, we set-up the proposed study, and hypothesize&#xD;
      that ARB's have a beneficial effect on RV ejection fraction in adult TOF patients with RV&#xD;
      dysfunction without severe valvular lesions.&#xD;
&#xD;
      Objective: to improve RV ejection fraction in adult TOF patients with RV dysfunction without&#xD;
      severe valvular lesions.&#xD;
&#xD;
      Study design: a prospective, multicenter, double-blind, randomized, placebo-controlled trial.&#xD;
      Follow up two years Study population: adult patients with Tetralogy of Fallot with right&#xD;
      ventricular dysfunction, defined as right ventricular ejection fraction &lt; 50% and without&#xD;
      severe valvular lesions Intervention: patients are randomized to receive either losartan 150&#xD;
      mg once daily, or placebo in the same regimen. Main study parameters/endpoints: the primary&#xD;
      endpoint is difference in change in RV ejection fraction, determined by cardiovascular&#xD;
      magnetic resonance imaging (CMR), between the treatment and the control group at two years&#xD;
      follow-up.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: All investigations, except blood analysis, are non-invasive and free of risk.&#xD;
      The burden for the patients mainly consists of the time that is consumed by the visits to the&#xD;
      clinic. At these visits time will be consumed by: history taking and physical investigation&#xD;
      (15 minutes); quality of life score (15 minutes); laboratory tests (6 times venopuncture,&#xD;
      total amount of blood withdrawn approximately 90ml). Cardiopulmonary exercise testing&#xD;
      (1hour), echocardiography (15 minutes) and CMR (45 minutes) are part of regular medical care.&#xD;
      Adverse effects from losartan are usually limited and consist of dizziness due to&#xD;
      hypotension, renal impairment, hyperkalemia and liver impairment. We expect no change or an&#xD;
      increase in RV function in the intervention group compared to the control group over the&#xD;
      two-year follow up period, which would be a great benefit for this young study population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricular ejection fraction</measure>
    <time_frame>two years</time_frame>
    <description>RV EF is measured by means of cardiovascular magnetic resonance imaging (CMR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RV volumes (CMR)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary regurgitation (CMR and echocardiography)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aortic root diameter (CMR and echocardiography)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiographic parameters for RV and LV function</measure>
    <time_frame>one year and two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximal exercise capacity (VO2 max)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization for heart failure</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the prevalence of (supra) ventricular arrhythmias</measure>
    <time_frame>within two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the serum ntproBNP levels</measure>
    <time_frame>one year and two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF 36 and SQUASH)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV mass (CMR)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV EF (CMR)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV volumes (CMR)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV mass (CMR)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Galectin-3 levels</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>circulating microRNA's</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Tetralogy of Fallot</condition>
  <condition>Heart Defects, Congenital</condition>
  <condition>Ventricular Dysfunction, Right</condition>
  <arm_group>
    <arm_group_label>Losartan 150mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 150mg daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <arm_group_label>Losartan 150mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo 150mg daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study, a subject must meet all of the&#xD;
        following criteria: adult age and mentally competent; and Tetralogy of Fallot; and right&#xD;
        ventricular dysfunction, defined as right ventricular ejection fraction 50% or lower as&#xD;
        measured by Cardiovascular Magnetic Resonance Imaging (CMR). Not more than moderate&#xD;
        tricuspid or pulmonary regurgitation or more than moderate pulmonary stenosis as measured&#xD;
        by CMR or echocardiography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incapable of giving informed consent&#xD;
&#xD;
          -  Hypersensitivity to losartan or any of its help substances&#xD;
&#xD;
          -  Contraindications for CMR&#xD;
&#xD;
          -  Previous or current angioedema whether or not in relation to the use of an ACE&#xD;
             inhibitor or ARB&#xD;
&#xD;
          -  Known bilateral renal artery stenosis&#xD;
&#xD;
          -  Current symptomatic hypotension&#xD;
&#xD;
          -  Estimated glomerular filtration rate of 30 ml/min or lower&#xD;
&#xD;
          -  Plasma potassium level of 5,5 mmol/L or higher&#xD;
&#xD;
          -  Moderate to severe liver disease: Child Pugh class B or C&#xD;
&#xD;
          -  Raised plasma transaminases level more than three times upper normal limit&#xD;
&#xD;
          -  Current treatment of hypertension with an ACE-inhibitor or ARB, which cannot be&#xD;
             discontinued&#xD;
&#xD;
          -  Current treatment with potassium chloride, trimethoprim, tacrolimus or cyclosporine&#xD;
             which cannot be discontinued&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Desire to have children within the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>J.P. Bokma</last_name>
    <email>j.p.bokma@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>B.J. Bouma</last_name>
    <email>b.j.bouma@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>J.P. Bokma</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>B.J.M. Mulder</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>B.J. Bouma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Antonius ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Radboud Universitair Medisch Centrum</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Berto J Bouma</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Losartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Ventricular Dysfunction, Right</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

